Menu

Axogen, Inc. AXGN

Full chart Compare
Set alert

Price alert · AXGN

All alert types
50.89 USD +0.25 (+0.49%)

At closeNov 10, 2026, 4:01 PM EST

50.89 0.00 0.00%

After hours · Nov 10, 4:01 PM ET

49.23 Day range 51.10
23.00 52-week range 52.91
YTD
+55.48%
1 year
+112.04%
Market cap
3.04B
Revenue (ttm)
266.93M
Profit margin
-11.96%
EPS (ttm)
-0.63
Shares out
59.73M
Forward P/E
72.14
YTD return
+55.48%
1-year return
+112.04%
Volume
1.04M
Avg volume
1.44M
Open
49.70
Previous close
50.64
Day's range
49.23 – 51.10
52-week range
23.00 – 52.91
Beta
1.15
Analysts
Strong Buy
Price target
59.09 (+16.1%)
Earnings date
Feb 23, 2027

5D -0.07 (-0.14%)

485052WedThuFriMonTue50.92

Key statistics

Enterprise value
2.70B
PEG ratio
99.04
Price / sales
11.39
Price / book
6.13
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
26.20%
Free cash flow
29.81M
Total cash
348.07M
Total debt
19.47M
Return on equity
-10.35%
Short % of float
9.76%
50-day average
42.77
200-day average
40.11

Financials — quick view

All financials
AXGN Revenue — quarterly 75.83M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
AXGN Net income — quarterly 2.33M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
AXGN EPS — quarterly 0.04
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

AXGN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 23, 2027Dec 30, 20260.15———
Oct 28, 2026Sep 30, 20260.13130.21+0.08+59.94%
Jul 29, 2026Jun 30, 20260.12140.120.00-1.15%
Apr 28, 2026Mar 31, 20260.120.07-0.05-41.67%
Feb 24, 2026Dec 31, 20250.088790.07-0.02-21.16%
Oct 29, 2025Sep 30, 20250.090.12+0.03+33.33%

Upgrades / downgrades

AXGN analyst upgrades and downgrades
DateFirmActionFromTo
Oct 29, 2026Canaccord GenuitymainBuyBuy
Oct 29, 2026Leerink PartnersmainOutperformOutperform
Oct 29, 2026BarclaysmainOverweightOverweight
Oct 29, 2026Truist SecuritiesmainBuyBuy
Oct 29, 2026Wells FargomainOverweightOverweight
Oct 29, 2026HC Wainwright & Co.mainBuyBuy

About Axogen, Inc.

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on AXGN — it syncs with the Stock Master app.

Insider holders

AXGN insider holders
InsiderRelationLatest transactionDateShares held
BEGAN MARC A.General CounselConversion of Exercise of derivative securityFeb 26, 202650,135
DALE MICHAEL DChief Executive OfficerSaleDec 9, 202563,537
DEVINNEY ERICK WAYNEOfficerSaleMar 15, 2026262,781
HARTLEY LINDSEY MARIEChief Financial OfficerSaleMay 6, 202665,146
KEMP JENS SCHROEDEROfficerSaleMay 6, 202672,451
LEVINE ALAN M.DirectorConversion of Exercise of derivative securityJun 17, 202650,893

Institution ownership

AXGN institution ownership
Holder% heldSharesValueReported
Blackrock Inc.7.40%4,419,208224.89MJun 29, 2026
Morgan Stanley4.60%2,747,924139.84MJun 29, 2026
First Light Asset Management, LLC4.60%2,748,361139.86MJun 29, 2026
Vanguard Capital Management LLC3.78%2,257,948114.91MJun 29, 2026
Artemis Investment Management Llp2.98%1,780,99290.63MSep 29, 2026
Geode Capital Management, LLC2.76%1,649,62083.95MSep 29, 2026

Fund ownership

AXGN fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.67%1,596,14981.23MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.31%1,380,75670.27MSep 29, 2026
Manager Directed Portfolios-Hood River Small-Cap Growth Fund1.83%1,095,48255.75MJul 30, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.02%609,72831.03MJun 29, 2026
T. Rowe Price New Horizons Fund, Inc.0.98%588,20029.93MJun 29, 2026
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund0.96%576,28729.33MAug 30, 2026